September 30, 2005 12:26 ET

Potential of Statins to Treat or Prevent Alzheimer's Disease Widely Recognized

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Sep 30, 2005) -

Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

The potential of statins for treating or preventing Alzheimer's disease has been widely recognized and has also been acknowledged in medical textbooks, for example the chapter in the current edition of Alzheimer's Disease, A Physician's Guide to Practical Management (ed. Richter R.W. and Richter B. Z.; Humana Press, 2004, pages 253-257), which reviews the evidence about the efficacy of statins in treating or preventing dementia.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential use of statins to treat Alzheimer's disease (AD) has also been the topic of much discussion in the peer-reviewed medical literature, both in terms of clinical data, (such as The Lancet Neurology (Sept. 2005; 4:521-2), Arch Neurol. (July 2005; 62:1047-51 Neurology (May, 2005; 64:1531-8); Arch Neurol. (May 2005; 62:753-7); J Neurol Sci. (Mar, 2005; 229-230:147-50); Arch Gen Psychiatry (Feb. 2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19), J Biol Chem (Aug 2005; M505268200), PLoS Med. (Jan. 2005; 2:e18); J Neurosci. (Jan. 2005; 25:299-307))

The potential for the use of statin drugs to treat or reduce the risk of Alzheimer's disease has also been featured in general media such as New York Times, Fortune magazine, Newsweek magazine, Los Angeles Times, and The Wall Street Journal.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com